<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01884402</url>
  </required_header>
  <id_info>
    <org_study_id>FPS-PEG-2010-01</org_study_id>
    <nct_id>NCT01884402</nct_id>
  </id_info>
  <brief_title>Observational,Prospective Study to Develop and Validate a Prognostic Tool to Optimize Therapy in Patients With HCV G1/4</brief_title>
  <acronym>OPTIM</acronym>
  <official_title>Observational,Post-authorization Prospective Study to Develop and Validate a Prognostic Tool for Optimizing Therapy in Patients With Hepatitis C Virus (HCV) Genotype 1 and 4.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective:

      • Develop and validate a tool towards patients with chronic hepatitis C genotype 1 and 4 to
      allow optimize treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Tool:

        1. Predicting the overall impact of prognostic factors (including the new factor of genetic
           polymorphism of the IL28B) on Sustained Viral Response (SVR).

        2. Identify those patients most likely to respond.

        3. Therapy and therefore optimize resources

      The validation tool will check into clinical practice its predictive power (it will consider
      its ability to calibrate and discriminate) and make correct inferences and interpretations of
      the scores obtained when applying.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained Viral Response (RVS)</measure>
    <time_frame>1 ½ years (72 weeks)</time_frame>
    <description>Measurement of HCV RNA negativization 24 weeks after treatment</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">770</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Pegasys, injection subcutaneous</arm_group_label>
    <description>HCV patients monoinfected or coinfected genotype 1/4 treated with Peginterferon alfa-2a and Ribavirin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2a</intervention_name>
    <description>Treatment as usual clinical practice</description>
    <arm_group_label>Pegasys, injection subcutaneous</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Treatment as usual clinical practice</description>
    <arm_group_label>Pegasys, injection subcutaneous</arm_group_label>
    <other_name>Copegus</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with chronic hepatitis C genotype 1 and 4 mono-or co-infected with HIV who meet
        the selection criteria described.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with &gt; 18 years old.

          -  Patients diagnosed with chronic hepatitis C in the presence of HCV RNA in plasma that
             meet criteria for initiating antiviral therapy in routine clinical practice
             conditions.

          -  Patients Genotype 1 and 4.

          -  Patients with the results of all the factors evaluable at the time of inclusion.

          -  Patients who have accepted their participation in the study through informed consent.

        Exclusion Criteria:

          -  Patients previously treated with interferon (IFN) and ribavirin (RBV).

          -  Patients with genotype 2, 3, 5 and 6.

          -  Patients with co-infection with hepatitis B.

          -  Patients with other liver diseases.

          -  Patients with any contraindications to the drugs used in the treatment of hepatitis C.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuel Romero-Gómez, Medicine</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Valme &amp; ciberEHD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fundación Pública Andaluza para la Gestión de la investigación en salud de Sevilla (FISEVI)</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2013</study_first_submitted>
  <study_first_submitted_qc>June 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2013</study_first_posted>
  <last_update_submitted>September 3, 2014</last_update_submitted>
  <last_update_submitted_qc>September 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

